Rallybio Corp RLYB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—NCSM, PSBQ, LAB, and RLYB
-
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?
-
Rallybio Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Rallybio Corporation - RLYB
-
RLYB Stock Alert: Halper Sadeh LLC is Investigating Whether Rallybio Corporation is Obtaining a Fair Price for its Shareholders
-
Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Shares Outstanding
- 5.31M
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 108.17
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 9
- Website
- https://www.rallybio.com
Valuation
|
Metric
|
RLYB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.78 |
Price/Sales | 111.66 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
RLYB
|
|---|---|
Quick Ratio | 11.30 |
Current Ratio | 12.92 |
Interest Coverage | — |
Quick Ratio
RLYB
Profitability
|
Metric
|
RLYB
|
|---|---|
Return on Assets (Normalized) | −6.42% |
Return on Equity (Normalized) | −6.95% |
Return on Invested Capital (Normalized) | −10.14% |
Return on Assets
RLYB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#F%&@J< | LOCK|cjB% | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<&^!RC | LOCK|MWWR? | $70B | |||
| argenx SE ADR
ARGX
| LOCK|^K%pM# | LOCK|$&d | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!bG&m% | LOCK|!?T | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<$s^QS? | LOCK|Lc^$ | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|%>n&>tG^ | LOCK|B<%#F | $25B | |||
| Moderna Inc
MRNA
| LOCK|<dl<@h! | LOCK|mJ | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|z$ynXN | LOCK|&x | $23B | |||
| Incyte Corp
INCY
| LOCK|>^T>Wn | LOCK|rbY | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|#T<^L!X | LOCK|gF> | $16B |
United States